Correlation Between Inhibrx and NextCure
Can any of the company-specific risk be diversified away by investing in both Inhibrx and NextCure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and NextCure into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and NextCure, you can compare the effects of market volatilities on Inhibrx and NextCure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of NextCure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and NextCure.
Diversification Opportunities for Inhibrx and NextCure
Very weak diversification
The 3 months correlation between Inhibrx and NextCure is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and NextCure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NextCure and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with NextCure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NextCure has no effect on the direction of Inhibrx i.e., Inhibrx and NextCure go up and down completely randomly.
Pair Corralation between Inhibrx and NextCure
Given the investment horizon of 90 days Inhibrx is expected to generate 0.63 times more return on investment than NextCure. However, Inhibrx is 1.58 times less risky than NextCure. It trades about -0.02 of its potential returns per unit of risk. NextCure is currently generating about -0.26 per unit of risk. If you would invest 1,486 in Inhibrx on September 24, 2024 and sell it today you would lose (26.00) from holding Inhibrx or give up 1.75% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Inhibrx vs. NextCure
Performance |
Timeline |
Inhibrx |
NextCure |
Inhibrx and NextCure Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inhibrx and NextCure
The main advantage of trading using opposite Inhibrx and NextCure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, NextCure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NextCure will offset losses from the drop in NextCure's long position.Inhibrx vs. Fate Therapeutics | Inhibrx vs. Sana Biotechnology | Inhibrx vs. Caribou Biosciences | Inhibrx vs. Arcus Biosciences |
NextCure vs. CytomX Therapeutics | NextCure vs. Spero Therapeutics | NextCure vs. Instil Bio | NextCure vs. Assembly Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Complementary Tools
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |